| |
| |
|
| Insider
Information: |
Svennilson Peter |
| Relationship: |
Director, 10% Owner |
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
21,988,435 |
|
|
Indirect Shares
|
28,546,447 |
|
|
| Direct
Value |
$116,365,202 |
|
|
|
Indirect Value
|
$274,329,670 |
|
|
| Total
Shares |
50,534,882 |
|
|
| Total
Value |
$390,694,873 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
32
|
4
|
|
Stock
price went up :
|
32
|
1
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
32.0
|
32.0
|
| Percentage
Gain/Loss : |
 66.6%
|
 -51.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immune Design Corp. |
IMDZ |
Managing Partner, 10% ... |
2019-04-02 |
0 |
2017-10-27 |
6,642,942 |
Premium* |
|
|
Constellation Pharmaceuticals Inc |
CNST |
10% Owner |
2021-02-17 |
2,584,957 |
2021-02-17 |
3,645,681 |
Premium* |
|
|
Gritstone Oncology, Inc. |
GRTS |
Director, 10% Owner |
2018-10-02 |
0 |
2018-10-02 |
3,102,934 |
Premium* |
|
|
Ngm Biopharmaceuticals Inc |
NGM |
Managing Partner, 10% ... |
2020-08-28 |
17,988,843 |
2020-08-28 |
190,000 |
Premium* |
|
|
Oric Pharmaceuticals, Inc. |
ORIC |
Director, 10% Owner |
|
0 |
2020-04-28 |
4,768,181 |
Premium* |
|
|
Revolution Medicines, Inc. |
RVMD |
Director |
2021-04-28 |
20,302 |
2021-04-28 |
3,145,258 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
|
Rapt Therapeutics, Inc. |
RAPT |
Director, 10% Owner |
2020-08-17 |
0 |
2020-09-22 |
5,630,497 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
116 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
475,957 |
|
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • • |
2020-04-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
75,000 |
|
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
– – • |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
83,333 |
|
- |
|
| IMDZ |
Immune Design Corp. |
Director |
– • • |
2014-07-29 |
4 |
A |
$0.00 |
$0 |
I/I |
2,762,926 |
2,762,926 |
0 |
- |
|
| CNST |
Constellation Pharmaceuti... |
Director |
– • • |
2018-07-23 |
4 |
A |
$0.00 |
$0 |
I/I |
4,666,888 |
4,677,939 |
0 |
- |
|
| GRTS |
Gritstone Oncology, Inc. |
Director |
– • • |
2018-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,102,934 |
3,102,934 |
0 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
I/I |
13,093,134 |
15,444,091 |
0 |
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • • |
2020-04-28 |
4 |
A |
$0.00 |
$0 |
I/I |
4,693,181 |
4,768,181 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • • |
2020-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,234 |
7,234 |
0 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
Managing Partner |
– – • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,672,548 |
686,274 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
I/I |
46,914 |
46 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
13,068 |
20,302 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2020-12-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,046,868) |
0 |
0 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
– – • |
2021-05-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,488,027) |
0 |
0 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
– – • |
2021-05-05 |
4 |
A |
$0.00 |
$0 |
I/I |
809,826 |
48,406 |
0 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
– – • |
2021-05-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
1,394,333 |
0 |
- |
|
| CNST |
Constellation Pharmaceuti... |
10% Owner |
– – • |
2020-12-14 |
4 |
OE |
$1.55 |
$46,666 |
D/D |
30,107 |
2,584,957 |
0 |
- |
|
| IMDZ |
Immune Design Corp. |
Director |
– • • |
2017-10-27 |
4 |
B |
$4.10 |
$10,992,100 |
I/I |
2,681,000 |
2,681,000 |
2.25 |
- |
|
| IMDZ |
Immune Design Corp. |
Managing Partner |
– – • |
2019-04-02 |
4 |
D |
$5.85 |
$38,861,211 |
D/D |
(6,642,942) |
0 |
0 |
- |
|
| IMDZ |
Immune Design Corp. |
Director |
– • • |
2016-09-20 |
4 |
B |
$6.25 |
$5,000,000 |
I/I |
800,000 |
800,000 |
2.25 |
- |
|
| CNST |
Constellation Pharmaceuti... |
10% Owner |
– – • |
2019-10-03 |
4 |
B |
$8.50 |
$680,000 |
I/I |
80,000 |
159,155 |
1.5 |
- |
|
| CNST |
Constellation Pharmaceuti... |
10% Owner |
– – • |
2019-10-03 |
4 |
B |
$8.50 |
$11,319,994 |
D/D |
1,331,764 |
6,009,702 |
2.45 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2019-10-09 |
4 |
B |
$10.26 |
$181,848 |
I/I |
17,724 |
16,184,631 |
1.5 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2019-10-16 |
4 |
B |
$10.26 |
$358,074 |
I/I |
34,900 |
16,323,079 |
2.25 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2019-10-15 |
4 |
B |
$10.31 |
$342,292 |
I/I |
33,200 |
16,288,179 |
2.25 |
- |
|
116 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
